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Chinese herbal medicine (CHM) in the treatment of chronic heart failure (CHF) patients
according to syndrome differentiation.
Methods: In this multicenter, randomized, double-blind, placebo-controlled clinical trial, a to-
tal of 220 CHF patients were assigned to receive CHM or placebo granules without decoction
according to syndrome differentiation in addition to their standard western treatment for 4
weeks. The change in the left ventricular ejection fraction (LVEF) was the primary outcome,
and the changes in the TCM syndrome scores (TCM-SS) and New York Heart Association func-
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Chinese herbal medicine for chronic heart failure 99Results: After 4 weeks of treatment, the mean changes in the LVEF (13.1  9.78 vs.
7.34  7.40, P < 0.001) and the TCM syndrome scores (34.2  24.6 vs. 23.5  25.2,
PZ 0.002) were better in the CHM group than in the placebo group. After two weeks of treat-
ment, the mean changes in the LVEF (9.26  7.83 vs. 4.72  5.60, P < 0.001) and the TCM syn-
drome scores (23.5  18.6 vs. 14.0  15.9, P < 0.001) were better in the CHM group than in
the placebo group. In addition, repeated-measures analysis of variance (ANOVA) indicated sig-
nificant time course effects of CHM versus placebo in the LVEF and TCM syndrome cores
(P < 0.001 for all). The distention of the jugular vein (P Z 0.021), expectoration
(PZ 0.044), abdominal distention (PZ 0.004), and rib pain (PZ 0.005) were significantly less
in the CHM group than in the placebo group after two weeks of treatment. Fatigue (PZ 0.001),
less gas and lazy words (P Z 0.001), dizziness (P Z 0.003), gasping for breath (P Z 0.027),
abdominal distention (P Z 0.011), nausea (P Z 0.001) and emesis (P Z 0.012) were signifi-
cantly less in the CHM group than in the placebo group after treatment for four weeks. After
four weeks of treatment, the change in the NYHA functional classification in the CHM group
was better than that in the placebo group (P < 0.001). There was one death in the placebo
group, and one patient in the CHM group experienced atrial fibrillation.
Conclusion: CHM treatment according to syndrome differentiation effectively improved the
LVEF, TCM-SS, and NYHA-FC in patients with CHF and also appeared to be safe. Thus, CHM
treatment could be used as an adjuvant therapy in the treatment of CHF (Clinical trial regis-
tration: NCT01939236).
ª 2014 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).Introduction
Heart failure (HF) can be defined as an abnormality of car-
diac structure or function leading to the failure of the heart
to deliver oxygen at a rate commensurate with the re-
quirements of themetabolizing tissues despite normal filling
pressures (or only at the expense of increased filling pres-
sures).1 In addition, according to the nature of the clinical
presentation, HF is divided into acute and chronic HF.1
Despite major improvements in the treatment of virtu-
ally all cardiac disorders, heart failure (HF) is an exception
because its prevalence is rising and only small prolongations
in survival have been achieved.2 The diagnosis and treat-
ment of cardiovascular disease (CVD) have developed
rapidly in the past several decades. The mortality of many
CVDs, with the exception of HF, has decreased. The annual
hospital discharge of subjects with a primary diagnosis of
HF has increased steadily since 1975, and the discharge rate
now exceeds 1 million per year, although it may be leveling
off in the United States.3,4
In 2003, a random sample survey of 15,518 urban or rural
residents between 35 and 74 years of age in China indicated
that the prevalence rate of heart failure was 0.9%. Ac-
cording to the result, there were approximately 4,000,000
HF subjects in China.5 Another retrospective investigation
of 10,714 HF subjects in the full-year segments of 1980,
1990, and 2000 was conducted in 42 hospitals in China, and
this study revealed that the underlying cause of HF in 45.6%
of HF subjects was coronary heart disease (CHD).6
The mortality of CHD has been reduced due to the wide
application of percutaneous coronary intervention and
coronary artery bypass grafting. The early mortality in
subjects with acute myocardial infarction may havedeclined by 75% during the past half-century;7 however, the
survivors still have CHD and remain at risk for subsequent
episodes of ischemic myocardial damage with further loss
of myocardium and possibly HF.
The western medicine (WM) treatment for HF is stan-
dardized around the world.8,9 The conventional therapeutic
approaches in HF management are angiotensin-converting
enzyme inhibitors (ACEI), b-adrenergic blockers, and di-
uretics. In China, the integrative treatment of western and
traditional Chinese medicine for HF is usually applied and
has been developed as a treatment model.8 CHM has been
used in China for thousands of years. Syndrome differenti-
ation and treatment variation are the basic principles of
TCM in the understanding and treatment of diseases. Syn-
drome differentiation is the comprehensive analysis of the
clinical information gained by the four main diagnostic TCM
procedures, namely, observation, listening, questioning,
and pulse analysis, and it is used to guide the choice of
treatment by CHM. We would like to test the hypothesis
that it is efficacious and safe for patients to take CHM
granules according to syndrome differentiation.
In this study, a multicenter, randomized, double-blind,
placebo-controlled trial was conducted. The aim was to
evaluate the efficacy and safety of CHM on CHF according
to syndrome differentiation.Materials and methods
Study design
This multicenter, randomized, double-blind, placebo-
controlled study was conducted in seven centers of four
Table 1 Allocation information of subjects with CHF.
Allocation information n Percent (%)
Research centers
Dongfang Hospital Affiliated
to BUCM
12 5.48
Zhengzhou Hospital of TCM 44 20.09
The Affiliated Hospital to
Changchun University of CM
28 12.79
Guang’anmen Hospital Affiliated
to China Academy of Chinese
Medicine Sciences
27 12.33
Hubei Provincial Hospital of TCM 36 16.44
Wuhan Hospital of TCM 36 16.44
Yichang Hospital of TCM 36 16.44
Treatment groups
CHM group 110 50.23
Placebo group 109 49.77
100 L. Luo et al.provinces in China from May 2010 to September 2012 and
was reported in accordance with the 2010 CORSORT
statements.10
The study was conducted according to the guidelines of
the Declaration of Helsinki and approved by the ethics
committee of Dongfang Hospital affiliated to Beijing Uni-
versity of Chinese Medicine (No. 201002102). All of the
subjects voluntarily signed an informed consent form
before enrollment.
Sample size estimation
The sample size calculation was calculated with the
following formula:
nZ
ðya þ ybÞ2

1þ 1=c

s2
d2
s2Zs2Z
S2eþCS2c
1þC ..d
2Z
xe xC

2
The estimated number of subjects in each group was
98.18012, and 196.36024 subjects are needed to have two
groups. The number was increased to 215.18012 assuming a
maximum dropout rate of less than or equal to 10%, and a
total of 220 subjects were included (110 subjects in each
group).
Participants
Diagnostic criteria
 Diagnostic criteria of CHF: 2007 China Guideline for the
Diagnosis and Treatment of CHF.8
 Heart function standard: The Criteria for Diagnosis and
Treatment of Heart Disease first published by the New
York Heart Association (NYHA).11
 TCM differentiation standard: according to the Guiding
Principles for the Clinical Study of New Drugs in Tradi-
tional Chinese Medicine released in 2002.12
Inclusion criteria
 The primary heart disease is CHD (with diagnosis for CHD
confirmed by coronary angiography, coronary computed
tomography, history of acute myocardial infarction,
limb-salvage Q wave for electrocardiogram (ECG), ECG
test, radionuclide examination support, etc.). The
included patients also had no history of hypertension or
of taking antihypertensive drugs and exhibited a blood
pressure under 160/100 mmHg.
 With a history of CHD, the following symptoms and signs
were observed: difficulty breathing, fatigue, fluid
retention (edema), left ventricular enlargement, end
systolic volume of left ventricular increase and LVEF
40, and NYHA functional classification II or III.
 Male or female subjects between 40 and 75 years old;
 If there was a “No” answer for any issue, the subject
could not enter into this research.Exclusion criteria
 Patients with one of the following diseases were
excluded: 1) serious valvular heart disease; 2) pericar-
dial disease; 3) cardiomyopathy; 4) congenital heart
disease; 5) acute myocardial infarction (AMI) within four
weeks; 6) cardiac shock; 7) acute myocarditis or serious
arrhythmia with variation in hemodynamics.
 Patients who suffer from pulmonary artery hypertension
caused by cor pulmonale, pulmonary embolism, or
stroke within a half year were also excluded.
 Patients who suffer from serious hepatic or renal
deficiency.
 Patients who suffer from diseases of blood system or
malignant tumor.
 Patients who suffer from diabetes mellitus with serious
complications, hyperthyrea or hypothyrea.
 Patients who suffer from infection.
 Pregnant women or women in lactation.
 Patients with mental disorders.
 Patients with infectious disease.
 Patients who took part in other trials within two months
of the present study.
The study was conducted in seven hospitals: Dongfang
Hospital Affiliated to Beijing University of Chinese Medicine
(BUCM), Zhengzhou Hospital of TCM in Henan Province, The
Affiliated Hospital to Changchun University of CM, Guan-
g’anmen Hospital Affiliated to China Academy of Chinese
Medicine Sciences, Hubei Provincial Hospital of TCM,
Wuhan Hospital of TCM, and Yichang Hospital of TCM
(Table 1). A total of 220 subjects were included in this
study.
Intervention
According to the 2007 China Guidelines for the Diagnosis
and Treatment of Chronic Heart Failure,8 all patients in the
two groups received the standardized western medicine
treatment, which includes angiotensin-converting enzyme
inhibitors (ACEI) or angiotensin receptor blockers (ARBs),
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CHM or placebo granules twice per day for four weeks ac-
cording to syndrome differentiation. The study focuses
mainly on the following four syndromes: qi deficiency,
blood stasis, water retention and yang deficiency. The CHM
drugs and placebo were prepared and provided by Beijing
Kangren Tang Pharmaceutical Co., Ltd. (Beijing, China). In
the CHM group, there were prescriptions for four syndromes
(qi deficiency, blood stasis, water retention and yang
deficiency), and the placebo was prepared with the same
appearance, smell and weight as the treatment adminis-
tered to the CHM group. The CHM drugs and placebo were
numbered according to a random number table that was
blinded to both the doctors and patients. The patients were
administered with CHM or placebo according to their syn-
dromes at the beginning and two weeks later.
The drugs for qi deficiency were composed of Astragalus
membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao
(huangqi, 60 g) and Codonopsis pilosula (Franch.) Nannf
(dangshen, 15 g). The drugs for blood stasis were composed
of Salvia miltiorrhiza Bge (danshen 15 g), Paeonia lactiflora
Pall (chishao, 15 g), Prunus davidiana (Carr.) Franch. (tao-
ren, 10 g) and Carthamus tinctorius L. (honghua, 10 g). The
drugs for water retention were composed of Alisma ori-
entalis (Sam.) Juzep (zexie 10 g), Polyporus umbellatus
(Pers.) Fries (zhuling, 15 g), Plantago asiatica L. (che qian
zi, 10 g), and Descurainia Sophia (L.) Webb. ex Prantl
(tinglizi, 10 g). The drugs for yang deficiency were
composed of Cinnamomum cassia Presl (rougui, 4.5 g) and
Aconitum carmichaelii Debx (zhifuzi, 10 g). All CHM herbs
were verified by high-performance liquid chromatography
(HPLC). Appendix Table lists the names of the CHM drugs in
Chinese and English.
The patients were prohibited from taking other Chinese
medicines during the treatment period. The granule quality
met the internal control standards of Beijing Kangren Tang
Pharmaceutical Co., Ltd. (Beijing, China) and complied
with GMP (Good Manufacturing Practice) standards.
The drugs for the treatment of hypertension (HBP),
diabetes mellitus, dyslipidemia and other diseases could be
used reasonably. In addition, the reason, name, and dosage
should be recorded in detail.Outcome measurements
The study was designed to evaluate the therapeutic effi-
cacy and safety of CHM treatment for CHF over a period of
four weeks. The primary endpoint was LVEF. The second
outcomes were the NYHA functional classification and the
TCM syndrome scores. The outcome measures were evalu-
ated after two and four weeks of treatment. The level of
LVEF was detected using the modified Simpson’s rule.13e15
Standardized training and conformance testing were
administered to all investigators before the study. Each
syndrome differentiation and TCM syndrome score was
evaluated by three physicians, and the results required
agreement from at least two physicians. A total of 65
clinical symptoms or signs were evaluated as TCM symp-
toms, and these were defined as TCM syndrome scores. The
standard of TCM symptoms are scored as without (0), very
light (1), light (2), medium (3), heavy (4), or very heavy (5).The rate of disappearance of symptoms or signs found for
the CHF patients were evaluated after two and four weeks
of treatment.
Safety evaluations were carried out before and after the
study, and these included general physical examinations,
routine blood, hepatic and renal function examinations,
and electrocardiogram. In addition, any adverse events
were reported and recorded in case report form (CRF).
Randomization and blinding
The random number table, drug codes and allocation
scheme of the groups were produced using the SAS statis-
tical software by the Center for Drug Clinical Pharmacology
Research of Dongzhimen Hospital affiliated to Beijing Uni-
versity of Chinese Medicine. The work associated with
compiling the blind number was completed by statistical
analysis personnel of Dongzhimen Hospital. This study took
two times to reveal the blind result. The data were locked
after the blinding review, at which point it was time to
reveal the grouping results (A and B groups). The blind
grouping results were then provided to the medical statis-
ticians. The blinding information of CHM or placebo was
revealed on the clinical summary meeting after the statis-
tical analysis.
Data analysis and statistics
The statistical analysis was performed using the Statistical
Package for the Social Sciences 16.0 (SPSS 16.0). The data
were entered twice into an EpiData database (Version 3.1)
by two independent data entry operators. The two data-
bases were compared for consistency, and all in-
consistencies were resolved by referring to the original data
collection CRF. In addition, the blinding results were
revealed twice. After the results were first revealed, the
statistical analysis of the differences between groups A and
B were initiated. After all of the statistical analyses were
finished, we revealed which group the CHM group was.
The data were analyzed based on the Intention-To-Treat
(ITT) and the per-protocol set (PPS) for adherence. The
results of the data analysis presented in this manuscript
were mainly based on ITT. The measurement data are
expressed as the means  standard deviation. The data for
the two groups was tested using a normal test and a ho-
mogeneity of variance test. The results are expressed as
95% confidence intervals (CIs). The Chi-square test or Wil-
coxon rank-sum test for categorical variables was used to
assess the comparability of the groups at baseline. The
differences in the characteristics of the subjects of the two
groups at baseline were compared by independent sample
t-test, and nonparametric statistics with the Man-
neWhitney U test were used for the comparisons between
groups, such as the course of disease and LVEF.
We described the changes in the LVEF and TCM syndrome
scores. The changes in the scores were compared between
the baseline and after two and four weeks of treatment
using paired t-tests to measure the effectiveness. Two-way
analysis of variance for repeated measures (ANOVA) was
used to compare the effects of two groups, and Wilcoxon
tests were used to compare the changes in categorical
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there were significant differences if P < 0.05. All of the
tests were two-tailed.
The safety evaluation included all of the randomized
patients. The adverse event rates were compared between
the two groups with the Chi-square test or Fisher’s exact
test (if the expected value for any count was less than 5).
Results
Participants and numbers analyzed
A total of 220 patients were recruited and randomly
assigned. There were 110 patients in the CHM group and 110
in the placebo group (Fig. 1, according to CONSORT 2010).
One patient in the placebo group was excluded for
failing to meet the inclusion criteria. During the treatment
period, 4 patients in the CHM group and 1 patient in the
placebo group were lost to follow-up because of poor
compliance, etc., and 1 patient in the placebo group
dropped out due to an adverse event.
The clinical characteristics of the CHF patients are
shown in Table 2. The mean  SD ages of the patients in the
CHM and placebo groups were 66.04  7.24 and
66.96  7.46 years (P Z 0.33). There was no significant
difference in any of the baseline clinical variables between
the two groups (Pgt >0.05).
Primary outcome
The levels of LVEF after two and 4 weeks of treatment were
significantly higher than those at baseline in both groups
(within-group: P < 0.001 for all, Table 3). After 4 weeks of
treatment, the level of LVEF in the CHM group was
increased by 13.1 compared with the baseline level (be-
tween-group: P < 0.001, Table 3 and Fig. 2). In addition,
there was a significant time course effect of CHM versus
placebo in the LVEF (repeated-measures ANOVA, P < 0.001,
Fig. 2). After 2 weeks of treatment, the level of LVEF in the
CHM group was increased by 9.26 compared with theFigure 1 Study design flow diagram.baseline level (between-group: P < 0.001, Table 3 and
Fig. 2).
Secondary outcomes
The TCM syndrome scores after 2 and 4 weeks of treatment
were significantly lower than the baseline scores in both
groups (within-group: P < 0.001 for all, Table 3). After 2
weeks of treatment, the TCM syndrome scores in the CHM
group were decreased by 23.5 compared with the baseline
(between-group: P < 0.001, Table 3 and Fig. 3). After four
weeks of treatment, the TCM syndrome scores in the CHM
group were decreased by 34.2 compared with the baseline
(between-group: P < 0.001, Table 3 and Fig. 3). In addition,
there was a significant time course effect of CHM versus
placebo in the TCM syndrome scores (repeated-measures
ANOVA, P < 0.001, Fig. 3).
In the CHM group, the distention of the jugular vein
(P Z 0.021), expectoration (P Z 0.044), abdominal
distention (P Z 0.004), and rib pain (P Z 0.005) were
significantly less than that observed in the placebo group
after 2 weeks of treatment (Table 4). The symptoms of
fatigue (P Z 0.001), less gas and lazy words (P Z 0.001),
dizziness (P Z 0.003), gasping for breath (P Z 0.027),
abdominal distention (P Z 0.011), nausea (P Z 0.001) and
emesis (PZ 0.012) were significantly less in the CHM group
compared with the placebo group after treatment for four
weeks (Table 4).
After 2 weeks of treatment, there was no significant
difference in the change in the NYHA functional classifica-
tion between the two groups (P Z 0.064, Table 3 and
Fig. 4), whereas after four weeks of treatment, there was
significant difference between the two groups (P < 0.001,
Table 3 and Fig. 5).
Adverse events
A total of 110 patients in the CHM group and 109 patients
in the placebo group were included in safety analysis
(Table 5). There was no obvious change in the safety
evaluations of the 219 patients before and after treatment.
The total number of adverse events was two in the CHM
group and three in the placebo group (PZ 0.683), and one
patient experienced a serious adverse event in each group.
One male patient in the placebo group died because of
acute heart failure induced by mood swing despite positive
rescue. One female patient in the CHM group suffered from
palpitations, and the electrocardiogram results indicated
atrial fibrillation (heart rate: 121 bmp), which was treated
with an intravenous drip of deslanoside injection, resulting
in an immediate return to normal. Other than these pa-
tients, there was no report of any serious adverse events
(SAEs) in both groups.
Discussion
We performed a multicenter, double-blinded, randomized
controlled study to confirm the efficacy and safety of CHM
for the treatment of CHF according to syndrome differen-
tiation. Compared to the placebo, CHM was more effective
in improving the LVEF, TCM syndrome scores and NYHA
Table 2 Baseline characteristics of the included patients.
CHM group (n Z 110)
(95% CI)
Placebo group (n Z 109)
(95% CI)
P
Age (years) 66.0  7.24 64.5, 67.2 67.0  7.46 65.5, 68.4 0.33
Sex
Male, n (%) 62 (56.4%) e 63 (57.8%) e 0.83
Female, n (%) 48 (43.6%) e 46 (42.2%) e
Race
Han 108 (98.2%) e 108 (99.1%) e 1.00
Other 2 (1.8%) e 1 (0.9%) e
Weight (kg) 65.8  12.4 63.4, 68.1 65.9  10.6 63.9, 67.9 0.95
Height (cm) 167  8.22 165, 168 166  6.73 165, 167 0.69
SBP (mmHg) 136  17.2 133, 139 136  19.1 132, 139 0.90
DBP (mmHg) 81.0  10.7 79.0, 83.0 79.5  11.5 77.3, 81.7 0.32
Heart rate (bmp) 80.7  15.0 77.8, 83.5 78.0  12.8 75.6, 80.4 0.16
Course of disease (years) 3.02  3.57 3.02, 3.57 3.51  4.21 2.70, 4.32 0.64
Medical history
History of MI 47 (42.7%) e 45 (41.3%) e 0.83
Arrhythmia 20 (18.2%) e 21 (19.3%) e 0.84
Diabetes mellitus 31 (28.2%) e 32 (29.4%) e 0.85
NYHA-FC
NYHA II 24 (21.8%) e 13 (11.9%) e 0.05
NYHA III 86 (78.2%) e 96 (88.1%) e
WM treatment
Beta blockers 78 (70.9%) e 78 (71.6%) e 0.92
ACEI/ARB 90 (81.8%) e 96 (88.1%) e 0.20
Diuretics 65 (59.1%) e 74 (67.9%) e 0.18
Digoxin 43 (39.1%) e 39 (35.8%) e 0.61
Spironolactone 37 (33.6%) e 37 (33.9%) e 0.96
Baseline
LVEF (%) 36.3  4.42 35.5, 37.1 36.4  4.13 35.6, 37.2 0.92
TCM-SS 68.1  26.0 63.2, 73.0 70.0  29.2 64.4, 75.5 0.81
Syndrome distribution
Qi deficiency 84 (77.1) e 82 (74.5) e 0.66
Blood stasis 85 (78.0) e 85 (77.3) e 0.90
Water retention 30 (27.5) e 34 (30.9) e 0.58
Yang deficiency 20 (18.3) e 17 (15.5) e 0.57
Chinese herbal medicine for chronic heart failure 103functional classification when combined with standardized
western medicine. We used a placebo with the same weight
and packaging as the CHM granules to achieve double
blindness for the CHF patients and researchers during the
study.
CHM has been widely used for the treatment of CHF, and
some studies have confirmed its efficacy.16e21 In the litera-
ture, qi deficiency (5731 cases, 16.40%), blood stasis (6377
cases, 18.25%), water retention (3445 cases, 9.86%) and yang
deficiency (6489 cases, 18.57%) are the common syndrome
differentiations of CHF patients.22 We performed an epide-
miological investigation of the syndrome differentiation of
CHF patients caused by CHD in 14 hospitals in China. The
investigation results indicated that qi deficiency (497 cases,
28.56%), blood stasis (448 cases, 25.75%), water retention
(186 cases, 10.69%) and yang deficiency (142 cases, 8.16%)
are the main syndrome differentiations of CHF patients.22
Therefore, we selected these four syndrome differentia-
tions as the main differentiations in this study. The drugs
used in this study are common and have been used for the
treatment of CHF for a long time. Although the previousstudies treated patients with stationary capsules or gran-
ules,18,19 we gave our patients drugs according to their syn-
drome differentiation. This study shows the efficacy of CHM
for the treatment of CHF according to syndrome differenti-
ation. LVEF is not an index of contractility because it de-
pends on volumes, preload, afterload, heart rate, and
valvular function and is not the same as the stroke volume.1
Similarly to previous studies,18,19 CHM treatment according
to syndrome differentiation improved the LVEF of CHF pa-
tients after two and four weeks of treatment. After two and
four weeks, the LVEF of the CHM group was higher than that
of the placebo group. The LVEF level of CHF patients could be
improved by treatment with the Qiliqiangxin capsule for 12
weeks.20 Compared with the Qiliqiangxin capsule, the effi-
cacy found in this study was significant after two weeks of
treatment because the baseline level of LVEF in this study
was higher than that obtained with the Qiliqiangxin capsule.
Repeated-measures ANOVA showed significant time
course effects of CHM versus placebo in the LVEF. A char-
acteristic of this study is that the LVEF levels of the CHF
patients included were not higher than 40%. Therefore, the
Table 3 Variation in the outcomes from baseline in the CHF patients.
Variables CHM (n Z 110) (95%CI) Placebo (n Z 109) (95%CI) Treatment effect (95% CI) P
LVEF (%)
2 weeks 9.26  7.83 (7.78.10.74) ** 4.72  5.60 (3.66.5.79) ** 4.54  0.921 (2.72.6.35) <0.001
4 weeks 13.1  9.78 (11.3.15.0) ** 7.34  7.40 (6.00.8.68) ** 5.78  1.15 (3.51.8.05) <0.001
TCM syndrome
scores
2 weeks 23.5  18.6 (26.8,-20.3) ** 14.0  15.9 (17.3,-10.7) ** 9.54  2.34 (14.1,-4.93) <0.001
4 weeks 34.2  24.6 (38.8,-29.5) ** 23.5  25.2 (28.2,-18.8) ** 10.6  3.37 (17.2,-4.00) 0.002
NYHA-FC
2 weeks
Improved by
2 grades
2 (1.82%) 0 0.064
Improved by
1 grade
44 (40.0%) 33 (30.3%)
No change 64 (58.2%) 76 (69.7%)
4 weeks
Improved by
2 grades
16 (14.5%) 3 (2.75%) <0.001
Improved by
1 grade
64 (58.2%) 54 (49.5%)
No change 29 (26.4%) 50 (45.9%)
Worsened by
1 grade
1 (0.909%) 2 (1.83%)
**P < 0.001 compared with the baseline within group.
104 L. Luo et al.findings could reveal the effect of CHM on CHF patients with
depressed LVEF. CHM treatment according to syndrome
differentiation may influence the long time prognosis
because LVEF is directly related to long-term prognosis.23Figure 2 Variation in LVEF over time. The data are shown as
the mean differences SE. ** P < 0.001 for the difference
between the baseline and the result after two or four weeks of
treatment (within-group difference). ## P < 0.001 for the
difference between the baseline and the result after two or
four weeks of treatment (between CHM and placebo group
difference). ff P < 0.001: time course effect of CHM versus
placebo by repeated-measures ANOVA. Repeated-measures
ANOVA indicated significant time course effects of CHM versus
placebo in LVEF (P < 0.001).The symptoms are a reflection of the TCM syndrome. The
TCM syndrome score is a semi-quantitative evaluation
method used to assess symptoms and has been used in the
efficacy evaluation in TCM clinical practice.24,25 ComparedFigure 3 Variation in TCM syndrome scores over time. The
data are shown as the mean differences SE. ** P < 0.001 for
the difference between the baseline and the result after two
or four weeks of treatment (within-group difference).
## P < 0.001 for the difference between the baseline and the
result after two or four weeks of treatment (between CHM and
placebo group difference). ff P < 0.001: time course effect of
CHM versus placebo by repeated-measures ANOVA. Repeated-
measures ANOVA indicated significant time course effects of
CHM versus placebo in TCM syndrome scores (P < 0.001).
Table 4 Rate of disappearance of symptoms or signs of CHF.
Symptoms or signs Time Group Disappearance (%) In-disappearance (%) c2 P
Fatigue 14 d Placebo 1 (0.99) 100 (99.01) 0.000 1.000
CHM 1 (0.98) 101 (99.02)
28 d Placebo 5 (4.95) 96 (95.05) 10.76 0.001*
CHM 22 (21.57) 80 (78.43)
Less gas and lazy words 14 d Placebo 5 (5.10) 93 (94.90) 2.484 0.115
CHM 13 (12.38) 92 (87.62)
28 d Placebo 11 (11.22) 87 (88.78) 11.03 0.001*
CHM 33 (31.43) 72 (68.57)
Dizziness 14 d Placebo 3 (4.23) 68 (95.77) 1.293 0.255
CHM 8 (10.53) 68 (89.47)
28 d Placebo 6 (8.45) 65 (91.55) 8.716 0.003*
CHM 22 (28.95) 54 (71.05)
Distention of the jugular vein 14 d Placebo 9 (20.45) 35 (79.55) 5.342 0.021*
CHM 21 (45.65) 25 (54.35)
28 d Placebo 24 (54.55) 20 (45.45) 0.155 0.694
CHM 28 (60.87) 18 (39.13)
Expectoration 14 d Placebo 8 (32.00) 17 (68.00) 4.075 0.044*
CHM 20 (62.50) 12 (37.50)
28 d Placebo 18 (72.00) 7 (28.00) 0.258 0.612
CHM 26 (81.25) 6 (18.75)
Gasping for breath 14 d Placebo 9 (9.18) 89 (90.82) 1.106 0.293
CHM 14 (15.22) 78 (84.78)
28 d Placebo 20 (20.41) 78 (79.59) 4.897 0.027*
CHM 33 (35.87) 59 (64.13)
Abdominal distention 14 d Placebo 7 (11.67) 53 (88.33) 8.276 0.004*
CHM 22 (35.48) 40 (64.52)
28 d Placebo 13 (21.67) 47 (78.33) 6.527 0.011*
CHM 28 (45.16) 34 (54.84)
Nausea 14 d Placebo 23 (46.00) 27 (54.00) 3.824 0.051
CHM 30 (68.18) 14 (31.82)
28 d Placebo 24 (48.00) 26 (52.00) 10.18 0.001*
CHM 36 (81.82) 8 (18.18)
Emesis 14 d Placebo 7 (43.75) 9 (56.25) e 0.073
CHM 17 (85.00) 3 (15.00)
28 d Placebo 9 (56.25) 7 (43.75) e 0.012*
CHM 19 (95.00) 1 (5.00)
Pain in ribs 14 d Placebo 9 (40.91) 13 (59.09) 7.955 0.005*
CHM 19 (86.36) 3 (13.64)
28 d Placebo 11 (50.00) 11 (50.00) 2.455 0.117
CHM 17 (77.27) 5 (22.73)
*P<0.05.
Chinese herbal medicine for chronic heart failure 105with other studies,18,19 we did not use the classifications of
“notable effective”, “effective”, and “ineffective” as the
evaluation criterion. Similarly to other studies,17e19 this
study found that CHM treatment can improve the TCM
syndrome scores of CHF patients. After two weeks of
treatment, the TCM syndrome scores of the CHF patients in
the CHM group decreased to levels lower than those
observed in the placebo group. Significant differences be-
tween the two groups could be observed during the treat-
ment period. We also found that the CHM treatment can
markedly relieve the symptoms and signs of CHF patients.
This effect was observed after two and four weeks of
treatment, which means that the effect of CHM on
different symptoms or signs may be observed at different
times.In this study, the NYHA functional classification of all
CHF patients was NYHA II or NYHA III. After two weeks of
treatment, there was no difference in the NYHA functional
classification between the two groups. After four weeks of
treatment, the variation in the NYHA functional classifica-
tion in the CHM group was better than that obtained in the
placebo group. The Qiliqiangxin capsule influences NYHA
functional classification after eight weeks of treatment20
because there were some patients with NYHA IV at base-
line. This finding means that the efficacy of CHM on the
NYHA functional classification requires a long treatment
time. However, caution should be taken in interpreting the
NYHA functional classification results. Although there was
no difference in the NYHA functional classification at
baseline, there were more CHF patients with NYHA Ⅱ in the
Figure 4 The variation of NYHA functional classification of 2
weeks.
Table 5 Summary of adverse events.
CHM group
(n Z 110)
Placebo group
(n Z 109)
P value
AEs 2 (1.82%) 3 (2.75%) 0.683
SAEs
Death 0 1 (9.17%)
Atrial
Fibrillation
1 (9.09%) 0
106 L. Luo et al.CHM group than in the placebo group. Further study is
needed to validate this finding.
With respect to safety, one patient in the placebo group
died, and one patient in the CHM group experienced atrial
fibrillation. There was no direct relationship between these
serious adverse events and intervention. In addition, there
were no differences in the AEs or SAEs between the two
groups. In total, the incidence of SAEs was low; therefore,
CHM treatment according to syndrome differentiation
appeared to be safe and well tolerated.
Compared with other studies,18,19 this study only
included CHF patients whose disease was caused by CHD.
Therefore, it cannot reflect the effect of CHM treatment
according to syndrome differentiation on CHF caused by
other heart diseases. In this study, we did not follow-up
with the patients for a long time after the treatment; thus,
it is difficult to draw a conclusion regarding the incidence of
cardiovascular events due to CHM in CHF patients and the
long-term prognosis. In addition, we did not measure the
N-terminal pro-B-type natriuretic peptide (NT-pro-BNP)
before and after treatment. The level of NT-pro-BNP isFigure 5 The variation of NYHA functional classification of 4
weeks. ## P < 0.001.associated with mortality and morbidity in HF patients.26,27
Therefore, a long-term follow-up randomized, placebo-
controlled study is necessary in the future to evaluate the
effect of CHM treatment according to syndrome differen-
tiation on CHF caused by different heart diseases.
Conclusion
This study found that CHM treatment according to syn-
drome differentiation could improve the LVEF, the TCM
syndrome scores, the disappearance of symptoms or signs
and the NYHA functional classification of CHF patients. CHM
treatment according to syndrome differentiation appeared
to be a safe and effective treatment for CHF as an assistant
treatment.
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AppendixTable List of CHM used in the study.
Syndrome differentiation English designation
of CHM
Chinese designation
of CHM
Place of origin Dosage (g)
Qi deficiency Huangqi 黄芪 Wuchuan County, Inner Mongolia
Autonomous Region
60
Dangshen 党参 Min county, Gansu Province 15
Blood stasis Danshen 丹参 Pingyi County, Shandong Province 15
Chishao 赤芍 Duolun County, Inner Mongolia
Autonomous Region
15
Taoren 桃仁 Zhuolu County, Hebei Province 10
Honghua 红花 Xihua County, Henan Province 10
Water retention Zexie 泽泻 Pengshan County, Sichuan Province 10
Zhuling 猪苓 Neiqiu County, Hebei Province 15
Cheqianzi 车前子 Xingan County, Jiangxi Province 10
Tinglizi 葶苈子 Xingan County, Jiangxi Province 10
Yang deficiency Zhifuzi 制附子 Jiangyou City, Sichuan Province 10
Rougui 肉桂 Xinyi City, Guangdong Province 4.5References
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